Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

13.00USD
22 Nov 2017
Change (% chg)

$-0.15 (-1.14%)
Prev Close
$13.15
Open
$13.10
Day's High
$13.20
Day's Low
$13.00
Volume
68,850
Avg. Vol
147,862
52-wk High
$18.95
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $584.06
Shares Outstanding(Mil.): 44.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.94 15.47
EPS (TTM): -- -- --
ROI: -- -10.73 11.81
ROE: -- -36.69 15.76

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

Nov 10 2017

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly ‍net loss per share $0.10​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Nov 07 2017

BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

* Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

Oct 18 2017

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

* Vanda Pharmaceuticals Inc - ‍announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

Sep 13 2017

BRIEF-Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​

* Vanda Pharmaceuticals Inc - ‍total net product sales were $42.1 million in Q2 of 2017​

Aug 02 2017

BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia

Jul 21 2017

BRIEF-Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc

* Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing Source text for Eikon: (http://bit.ly/2rwELbT) Further company coverage:

Jun 19 2017

Earnings vs. Estimates